StockData
SKYANasdaqFinance ServicesFiscal year ends December 31Also trades as SKYAW

SkyAI, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$2.79+0.14 (+5.28%)

Close on Oct 19, 2026

Market cap
$201.14M
P/E (TTM)
–
Dividend yield
–

About SkyAI

Finance Services, SIC 6199

Sharps Technology, Inc. is a medical device sales and distribution company that specializes in marketing and distributing syringe products along with related drug-delivery systems. The enterprise previously designed and manufactured a range of conventional and safety syringes for specialty, clinical, and pharmaceutical uses, and it markets remaining inventory to healthcare providers, hospitals, medical supply organizations, and clinics. In addition to its medical distribution business, the company operates a digital asset treasury strategy dedicated to acquiring and holding Solana tokens, engaging in native staking and selective derivative transactions.

The company distributes its medical products across domestic and international markets. Sharps Technology maintains its principal executive offices in Melville, New York. Its operations include treasury oversight functions that coordinate digital asset management alongside third-party advisory partners.

Summary of the business section of SkyAI's latest annual report, written by StockData.

Company profile

Company

Legal name
SkyAI, Inc.
Headquarters
Melville, NY
Address
105 Maxess Road, Ste. 124 11747
Phone
(631) 574-4436
Employees
55, Dec 31, 2024
Industry
Finance Services
Incorporated in
Nevada
Fiscal year ends
December 31
Auditor
PKF OConnor Davies, LLP, New York, New York

Stock & identifiers

Ticker
SKYA
Other tickers
SKYAW
Exchange
Nasdaq
IPO date
Apr 15, 2022
Shares outstanding
43M, Aug 4, 2026
Public float
$5.57M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-300 reverse, Apr 28, 2025; 1-for-22 reverse, Nov 14, 2024; 1-for-22 reverse, Oct 16, 2024
SEC CIK
1737995
CUSIP
82003F309
ISIN
US82003F3091
EIN
82-3751728

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Yuwen ZhangChief Investment Officer, Director14,040
Andrew R. CrescenzoChief Financial Officer, Director40,000
Arthur LevineChief Financial Officer–
Timothy James RuemlerDirector35,218
Brenda Baird SimpsonDirector20,000
Jason L. MonroeDirector80,000
Soren Bo ChristiansenDirector80,000
Paul K. DannerDirector400,000
Robert Michael HayesDirector100,000

Employees

Headcount reported in annual reports

“We have fifty-five full-time employees, two of which are our Chief Executive Officer and Chief Financial Officer, and retain the services of additional personnel, as needed, on an independent contractor basis to support R&D, Finance, Marketing and Regulatory areas.”

Corporate history

Events identified from SEC filings